GP9
Platelet glycoprotein IX
Also known as: CD42a, GPIX, GPIX_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P14770
- Gene
- GP9
- Ensembl
- ENSG00000169704
- Chromosome
- 3
- Canonical length
- 177 aa
- Protein class
- CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Plasma membrane,Cytosol
OverviewNCBI Gene
This gene encodes a small membrane glycoprotein found on the surface of human platelets. It forms a 1-to-1 noncovalent complex with glycoprotein Ib, a platelet surface membrane glycoprotein complex that functions as a receptor for von Willebrand factor. The complete receptor complex includes noncovalent association of the alpha and beta subunits with the protein encoded by this gene and platelet glycoprotein V. Defects in this gene are a cause of Bernard-Soulier syndrome, also known as giant platelet disease. These patients have unusually large platelets and have a clinical bleeding tendency. [provided by RefSeq, Oct 2008]
Canonical amino-acid sequenceUniProt
177 residues, UniProt reviewed canonical sequence.
>P14770|GP9
1 MPAWGALFLL WATAEATKDC PSPCTCRALE TMGLWVDCRG HGLTALPALP ARTRHLLLAN
61 NSLQSVPPGA FDHLPQLQTL DVTQNPWHCD CSLTYLRLWL EDRTPEALLQ VRCASPSLAA
121 HGPLGRLTGY QLGSCGWQLQ ASWVRPGVLW DVALVAVAAL GLALLAGLLC ATTEALDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against GP9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.39
- Highest tissue expression
- 8.8 nTPM
Expression across tissuesHPA
Tissue
- spleen: 8.8 nTPM
- bone marrow: 4.8 nTPM
- lung: 3.2 nTPM
- testis: 1.7 nTPM
- choroid plexus: 0.6 nTPM
- liver: 0.3 nTPM
Single-cell type
- platelets: 3,990 nCPM
- megakaryocytes: 952 nCPM
- megakaryocyte progenitors: 108 nCPM
- late spermatids: 30 nCPM
- early spermatids: 18 nCPM
- hofbauer cells: 3.4 nCPM
Immune cell
- total PBMC: 52 nTPM
- basophil: 29 nTPM
- neutrophil: 14 nTPM
- plasmacytoid DC: 3 nTPM
- classical monocyte: 1.2 nTPM
- intermediate monocyte: 0.7 nTPM
Brain region
- choroid plexus: 1.3 nTPM
- cerebral cortex: 0.8 nTPM
- amygdala: 0.2 nTPM
- cerebellum: 0.2 nTPM
- hypothalamus: 0.2 nTPM
- medulla oblongata: 0.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about GP9.
Disease | AllUniProt
Conditions GP9 is implicated in, by any mechanism.
- Bernard-Soulier syndrome (BSS) MIM:231200
Disease | GeneticClinVar
29 pathogenic / likely-pathogenic of 169 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Bernard Soulier syndrome
- Bernard-Soulier syndrome type C
- Macrothrombocytopenia
- Thrombocytopenia
- GP9-related disorder
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.46
- gnomAD pLI
- 0.48
- gnomAD missense Z
- 0.16
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- blood coagulation
- blood coagulation, intrinsic pathway
- cell adhesion
- megakaryocyte development
- positive regulation of platelet activation
- release of sequestered calcium ion into cytosol
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads GP9 as an antibody target. Whether an autoantibody or antibody against GP9 could matter depends on whether native GP9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
GP9 is annotated at the cell surface, where native GP9 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label GP9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...